Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment

Nutritional Neuroscience

Volumn 15, Issue 2, 2012, Pages 46-54

  Rondanelli, Mariangela ^a   Opizzi, Annalisa ^a   Faliva, Milena ^a   Mozzoni, Marco ^a   Antoniello, Neldo ^a   Cazzola, Roberta ^b   Savarè, Rita ^c   Cerutti, Renata ^c   Grossi, Enzo ^c   Cestaro, Benvenuto ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Bracco SpA   (Italy)

Author keywords

DHA; Dietary supplement; Melatonin; Mild cognitive impairment; Phospholipids; Tryptophan

Indexed keywords

ALPHA TOCOPHEROL; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; MELATONIN; NEUROPROTECTIVE AGENT; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PLACEBO; TRYPTOPHAN;

AGED; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; CONTROLLED STUDY; CORSI TEST; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMULSION; FEMALE; GERIATRIC DEPRESSION SCALE; HUMAN; INTEGRATION; LONG TERM MEMORY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MINI NUTRITIONAL ASSESSMENT; NEUROLOGIC EXAMINATION; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; OLFACTORY MEMORY; PHONETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REY AUDITORY VERBAL LEARNING TEST; REY OSTERRIETH COMPLEX FIGURE; SENSITIVITY ANALYSIS; SHORT STORY TEST; SHORT TERM MEMORY; SNIFFIN STICKS OLFACTION TEST; SPATIAL MEMORY; TREATMENT OUTCOME; VERBAL MEMORY; WEIGL SORTING TEST;

AGED, 80 AND OVER; ATTENTION; BODY COMPOSITION; COGNITION; DIET; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EMULSIONS; FEMALE; HUMANS; LINEAR MODELS; MALE; MELATONIN; MEMORY, LONG-TERM; MEMORY, SHORT-TERM; MENTAL RECALL; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; NUTRITIONAL STATUS; PHOSPHOLIPIDS; TRYPTOPHAN; VERBAL LEARNING;

EID: 84858771355     PISSN: 1028415X     EISSN: 14768305     Source Type: Journal    
DOI: 10.1179/1476830511Y.0000000032     Document Type: Article

References (58)

1. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet 2006;367: 1262-70.
2. Eckert GP, Cairns NJ, Müller WE. Piracetam reverses hippocampal membrane alterations in Alzheimer's disease. J Neural Transm 1999;106:757-61.
3. Zainaghi IA, Forlenza OV, Gattaz WF. Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology (Berl) 2007;192:547-53.
4. Hashimoto K. Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Pat CNS Drug Discov 2006; 1:43-53.
5. Clement AB, Gimpl G, Behl C. Oxidative stress resistance in hippocampal cells is associated with altered membrane fluidity and enhanced nonamyloidogenic cleavage of endogenous amyloid precursor protein. Free Radic Biol Med 2010;48:1236-41.
6. Scheuer K, Rostock A, Bartsch R, Müller WE. Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry 1999;32(Suppl 1): 10-6.
7. Schaeffer EL, Gattaz WF. Requirement of hippocampal phos- pholipase A2 activity for long-term memory retrieval in rats. J Neural Transm 2007;114:379-85.
8. Carriè I, Abellan-Van Kan G, Rolland Y, Gillette-Guvonnet S, Vellas B. PUFA for prevention and treatment of dementia? Curr Pharm Des 2009;15:4173-85.
9. Hooijmans CR, Graven C, Dederen PJ, Tanila H, van Groen T, Kiliaan AJ. Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res 2007;1181:93-103.
10. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005;25:3032-40.
11. Grundt H, Nilsen DW, Mansoor MA, Nordøy A. Increased lipid peroxidation during long-term intervention with high doses of n-3 fatty acids (PUFAs) following an acute myocardial infarction. Eur J Clin Nutr 2003;57:793-800.
12. Cazzola R, Russo-Volpe S, Miles EA, Rees D, Banerjee T, Roynette CE, et al. Age- and dose-dependent effects of an eico-sapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. Atherosclerosis 2007;193:159-67.
13. Wiklund O, Mattsson L, Bjömheden T, Camejo G, Bondjers G. Uptake and degradation of low density lipoproteins in athero-sclerotic rabbit aorta: role of local LDL modification. J Lipid Res 1991;32:55-62.
14. Nenseter MS, Drevon CA. Dietary polyunsaturates and peroxi-dation of low density lipoprotein. Curr Opin Lipidol 1996;7:8-13.
15. Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003;126:1-27.
16. Mallick BN, Thakkar M, Gangabhagirathi R. Rapid eye movement sleep deprivation decreases membrane fluidity in the rat brain. Neurosci Res 1995;22:117-22.
17. Sawazaki S, Hamazaki T, Yazawa K, Kobayashi M. The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: a double-blind placebo-controlled study. J Nutr Sci Vitaminol (Tokyo) 1999;45:655-65.
18. Hamazaki T, Sawazaki S, Nagasawa T, Nagao Y, Kanagawa Y, Yazawa K. Administration of docosahexaenoic acid influences behavior and plasma catecholamine levels at times of psychological stress. Lipids 1999;34(Suppl):S33-7.
19. Rondanelli M, Opizzi A, Monteferrario F, Antoniello N, Manni R, Klersy C. The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial. J Am Geriatr Soc 2011;59:82-90.
20. Terry AV, Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008;195:30-8.
21. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegen- erative disorders. Trends Neurosci 2004;27:589-94.
22. Porter RJ, Lunn BS, Walker LL, Gray JM, Ballard CG, O'Brien JT. Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. Am J Psychiatry 2000;157: 638-40.
23. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. J Am Med Assoc 1995;273:1274-8.
24. Petersen RC, Waring SC, Smith GE, Tangalos EG, Thibodeau SN. Predictive value of APOE genotyping in incipient Alzheimer's disease. Ann NY Acad Sci 1996;802:58-69.
25. Tierney MC, Szalai JP, Snow WG, Fisher RH, Tsuda T, Chi H, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996;46:149-54.
26. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
27. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist 1970;10:20-30.
28. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983;17:37-49.
29. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL (ed) Clinical gerontology: a guide to assessment and intervention. New York: The Haworth Press; 1986. p. 165-73.
30. Spinnler H, Tognoni G. Taratura e standardizazione ltaliana ditest neuropsicologici. Ital J Neurol Sci 1987;(Suppl 8 6):7-120.
31. Carlesimo CA, Caltagirone C, Gainotti G, Nocentini U. Batteria per la valutazione del deterioramento mentale: standardizza-zione e affidabilità diagnostica nell'identificazione di pazienti affetti da sindrome demenziale. Arch Psicol Neurol Psichiatr 1995;56:471-88 (in Italian).
32. Caffarra P, Vezzadini G, Dieci F, Zonato F, venneri A. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 2002;22:443-7.
33. Frisancho AR. New standards of weight and body composition by frame size and height for assessment of nutritional status of adults and the elderly. Am J Clin Nutr 1984;40:808-19.
34. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: the mini nutritional assessment as part of the geriatric evaluation. Nutr Rev 1996;54:S59-65.
35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
36. Dalla Barba G, Traykov L, Baudic S. Neuropsychological examination in dementia. In: Duyckaerts C, Litvan C (eds.) Handbook of clinical neurology, Vol. 89 (3rd series) dementias. Amsterdam: Elsevier B.V.; 2008.
37. Jacova C, Kertesz A, Blair M, Fisk JD, Feldman HH. Neuropsychological testing and assessment for dementia. Alzheimer's and Dementia 2007;3:299-317.
38. Brown J, Brown LA. Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study. Br Med J 2009;338:b2030.
39. Kamphuis PJ, Scheltens P. Can nutrients prevent or delay onset of Alzheimer's disease? J Alzheimer Dis 2010;20:765-75.
40. Giesbrecht T, Rycroft JA, Rowson MJ, De Bruin EA. The combination of L-theanine and caffeine improves cognitive performance and increases subjective alertness. Nutr Neurosci 2010;13: 283-90.
41. Lamaziere A, Richard D, Barbe U, Kefi K, Bausero P, Wolf C, et al. Differential distribution of DHA-phospholipids in rat brain after feeding: a lipidomic approach. Prostaglandins Leukot Essent Fatty Acids 2011;84:7-11.
42. Gazzani G, Fioravante D, Moretti M, D'Angelo L, Broccali G. Studio sulla biodisponibità 'in vivo' degli acidi polinsaturi degli oli marini emulsionati con fosfolipidi di soia. Bollettino Cardiologico 1988;3:19-21.
43. Gazzani G, Fioravante D, Moretti M, D'Angelo L, Broccali G. Studio degli effetti nell'uomo della somministrazione di oli marini emulsionati con fosfolipidi di soia. Bollettino Cardiologico 1988;3:22-4.
44. Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr Neuropharmacol 2010;8:218-27.
45. Feng Z, Chang Y, Cheng Y, Zhang BL, Qu ZW, Qin C, et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 2004;37:129-36.
46. Matsubara E, Bryant-Thomas T, Pacheco, Quinto J, Henry TL, Poeggeler B, Herbert D. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003;85:1101-8.
47. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melato- nin in a transgenic model of Alzheimer disease. J Pineal Res 2009;47:82-96.
48. Mahlberg R, Walther S, Kalus P, Bohner G, Haedel S, Reischies FM, et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. Neurobiol Aging 2008;29: 203-9.
49. Uchida K, Okamoto N, Ohara K, Morita Y. Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brainn Res 1996;717:154-9.
50. Skene DJ, Vivien-Roels B, Sparks DL, Hunsaker JC, Pévet P, Ravid D, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 1990;528:170-4.
51. Wu YH, Feenstra MG, Zhou JN, Liu RY, Toranõ JS, Van Kan HJ, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003;88:5898-906.
52. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003;35:125-30.
53. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: assessment in a clinical trial of melatonin replacement. Sleep 1998; 21:52-68.
54. Garzón C, Guerrero JM, Aramburu O, Guzmán T. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging Clin Exp Res 2009; 21:38-42.
55. Mowla A, Mosavinasab M, Haghshenas H, Borhani Haghighi A. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2007;27:484-7.
56. Isaia G, Mondino S, Germinara C, Cappa G, Aimonino-Ricauda N, Bo M, et al. Malnutrition in an elderly demented population living at home. Arch Gerontol Geriatr 2011 Jan 12, 53(3):249-51 [Epub ahead of print].
57. Fusetti M, Fioretti AB, Silvagni F, Simaskou M, Sucapane P, Necozione S, et al. Smell and preclinical Alzheimer disease: study of 29 patients with amnesic mild cognitive impairment. J Otolaryngol Head Neck Surg 2010;39:175-81.
58. Eibenstein A, Fioretti AB, Simaskou MN, Sucapane P, Mearelli S, Mina C, et al. Olfactory screening test in mild cognitive impairment. Neurol Sci 2005;26:156.